First Discussion of 2021 AMR Benchmark Findings: A One Health Spotlight on Access, Innovation and Stewardship

This virtual event will highlight the importance of private sector action against superbugs from the human, animal and environmental perspectives. New research presented from the 2021 Antimicrobial Resistance Benchmark will unpack the actions of pharmaceutical companies, as well as the latest research into antimicrobial stewardship in the animal health industry from the FAIRR Initiative’s Feeding Resistance report.

Keynote remarks will be delivered by Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance. A panel of experts from the investing, policy and industry worlds will discuss where greater alignment can increase the pace of action to tackle the urgent global health and economic threat of drug-resistant infections.

A lens on global health security
The coronavirus pandemic has brought new attention and comprehension from governments, multilateral organisations, investors, economists, pharmaceutical and animal protein companies alike regarding the significance and potential impact of global health threats. Furthermore, the pandemic has emphasised the need for greater investments in health security to prevent future global health catastrophes from occurring, with antimicrobial resistance at the top of the list.  

World Antimicrobial Awareness Week, running from 18-24 November 2021, offers a timely moment to take stock of the progress made from a One Health approach since the launch of the Investor Action on AMR and to unpack where more progress is urgently needed.

Are pharma companies doing enough to slow the superbugs?
The findings from the 2021 Antimicrobial Resistance Benchmark will be presented as part of the agenda. It will provide the latest deep dive into whether pharmaceutical companies are doing enough to curb drug resistance.

• 21 pathogens: R&D pipelines targeting high-risk bacteria and fungi designated by WHO and/or the CDC as posing the greatest threat from drug resistance.

• 166 products: 166 medicines and vaccines, including both on-patent and off-patent products.

• 102 countries: The access metrics cover countries meeting the following criteria: (1) national income level; (2) level of development; (3) scope and scale of inequality; (4) infectious disease burden.

• 17 companies: Nine generic medicine manufacturers and eight large research-based pharmaceutical companies.

Watch the video recording

Please click here to watch the full video.